Immunogenicity of Biosimilar Therapeutics in Drug Development (Q167968)

From geokb
Revision as of 12:25, 8 September 2024 by Sky (talk | contribs) (‎Changed an Item: moved OpenAlex ID to its dedicated external ID datatype for consistency)
Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.
  • Biosimilars
  • Immunogenicity
  • Bioanalytical Methods
  • Therapeutic Proteins
  • Dried Blood Spots
  • Erythropoietin Antibodies
  • Monoclonal Antibodies
  • Regulatory Guidelines
  • Biopharmaceuticals
  • Clinical Outcomes
Language Label Description Also known as
English
Immunogenicity of Biosimilar Therapeutics in Drug Development
Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.
  • Biosimilars
  • Immunogenicity
  • Bioanalytical Methods
  • Therapeutic Proteins
  • Dried Blood Spots
  • Erythropoietin Antibodies
  • Monoclonal Antibodies
  • Regulatory Guidelines
  • Biopharmaceuticals
  • Clinical Outcomes

Statements

0 references
0 references